Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 07, 2005. The report details corporate actions regarding share repurchases and updates on directors' interests in company shares held through various employee trusts and plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to share transactions:
- Share Repurchase Price: 13.2755 pence per share.
- Employee Plan Sale Price: 13.152 pounds per share.
- US Retirement Plan ADR Price: $48.64 average price.
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury stock purchase and adjustments in employee benefit trust holdings:
- Treasury Shares: The Company purchased 210,000 ordinary shares on March 04, 2005. Following this transaction, the Company holds 77,058,000 shares in Treasury.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) stands at 5,862,965,890.
- Trust Movements:
- 144,296 shares were transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- 231 shares were sold and 798 shares were transferred from the SmithKline Beecham Employee Benefit Trust under the Annual Investment Plan.
- The GlaxoSmithKline US Retirement Savings Plan saw its ADR holdings decrease from 18,459,732 to 18,351,337.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure of share movements and director interests.
Key Facts for Investor Verification
- Verify the impact of the 210,000 share buyback on earnings per share (EPS) in subsequent quarterly reports.
- Confirm the total authorized share buyback program limits and remaining capacity following this transaction.
- Monitor the aggregate number of shares held in Treasury (77,058,000) for potential future reissuance or cancellation.
- Review the specific terms of the employee trusts mentioned to understand potential dilution or voting rights implications.